Breast Cancer

Written by Erica Stupfel

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

ClinicalTrials.gov ID NCT06058377

Sponsor National Cancer Institute (NCI)

Information provided by National Cancer Institute (NCI) (Responsible Party)

Trial Information: https://clinicaltrials.gov/study/NCT06058377

VISIT WEBSITE

Call to learn more: 253-220-5003

Erica Stupfel

e*design Creative Services specializes in making professional design available to small companies and individuals. I understand the importance in brand identity and how a positive visual representation of your product or service can make the difference between success and failure. Your ideas and vision combined with my marketing and design expertise will be a sure success story.

https://www.edesigncreative.com
Previous

Gastrointestinal (GIST)
Next

Blood Cancers